Multimodal LLMs: Auditing AI’s Impact on Clinical Documentation

The healthcare field is changing fast as generative AI grows from simple text models into complex multimodal platforms. This shift brings new power to clinical documentation auditing, but it also creates new complexities that force investors to do their homework. You have to understand the new safety standards and audit frameworks to tell the difference between a reliable AI health product and one that’s a massive liability risk.

The Multimodal Revolution in Clinical Documentation

Clinical documentation audits have always been a grind, a manual, human-led process that leans heavily on structured text and coded data. LLMs started to automate parts of it, but the real change is happening with multimodal AI. These new models can process and understand different kinds of data at the same time: clinical notes, X-rays, MRIs, ECGs, even audio from a patient visit. Think about an AI that doesn’t just read a doctor’s dictated note, but also checks it against the patient’s chest X-ray and cardiac rhythm strip, finding subtle discrepancies or confirming a diagnosis with an integration that was impossible before. This capability is set to completely change the speed and accuracy of doc audits, which helps with compliance and billing, and in the end makes patients safer by catching errors a human might miss. But with that power comes a big headache in validation and oversight, especially when you start asking where the training data came from and how you can trust the AI’s complex conclusions.

Evaluating Foundational Models: CHAI Guidelines and Regulatory Pathways

So if you’re a healthcare VC or growth equity investor, how do you actually vet the safety and reliability of platforms built on these AI models? The big players like OpenAI and Google Cloud are building the foundational models that a lot of these new health AI tools run on. The Coalition for Health AI (CHAI) is the key group working to build consensus on how to evaluate these systems for clinical use, and their draft framework is an essential checklist for any investor. On June 26, 2024, CHAI released that draft framework for responsible health AI, which is now open for public comment. When you’re evaluating a vendor who’s using a foundational model from a provider like OpenAI or Google Cloud, you have to dig into how they’re handling CHAI’s recommendations, for example:

• Data Governance and Provenance: You need to know exactly where they got their training data for every single modality, images, text, signals, and what its biases and representativeness look like. This is where you confirm they’re respecting patient privacy and getting data ethically.
• Multimodal Alignment and Consistency: You have to verify that what the AI concludes from one type of data doesn’t contradict what it sees in another. Does its reading of a clinical note actually match its analysis of the attached MRI scan?
• Robustness to Adversarial Attacks and Perturbations: How does the model hold up when you feed it messy, incomplete, or even deliberately faked multimodal data? Because that’s what the real world looks like. You need to assess its performance under stress.
• Explainability and Interpretability: You must demand the vendor show you how the AI got to its answer, which is especially critical when it’s synthesizing complex inputs from multiple sources. This isn’t a “nice-to-have”. It’s fundamental for clinical accountability and for catching any potential algorithmic drift over time.

The FDA’s Digital Health Action Plan makes it clear these aren’t just academic concerns. While the FDA is scheduling public workshops on generative AI safety FDA public workshop schedules on generative AI safety, it also put out a discussion paper on regulating these devices and is asking for feedback. They’ve also got workshops on the books for AI in drug development, including one on August 6, 2024, and another on October 7, 2025. Right now, regulators will often classify these tools as Software as a Medical Device (SaMD) if they’re making diagnostic or treatment suggestions. Any vendor has to show a clear regulatory path, either through a 510(k) clearance or a De Novo classification if the tech is truly new. And for any company that’s serious, a Quality Management System (QMS) that’s compliant with ISO 13485 is absolutely non-negotiable.

Red Flags and Positive Signals in Vendor Due Diligence

For investors, the diligence on these multimodal AI health tools has to go way deeper than a typical software evaluation.

Training Data Source and Clinical Accountability

Here’s a huge red flag: a vendor who’s cagey about the granular details of their multimodal training data. That includes the demographic mix, the types of clinical settings it came from, and its quality across all modes. On the flip side, a very positive signal is a vendor that has built a real data advantage with its own proprietary, well-curated, and clinically validated datasets. This usually means they have partnerships with top health systems, which ensures their data is relevant to the real world and was gathered ethically. You should be asking for hard evidence of their data annotation procedures and any independent clinical validation studies they’ve run.

Published Outcomes Evidence

The lack of published outcomes evidence is a major concern, particularly if there are no peer-reviewed studies to back up claims of clinical utility and safety. An early-stage company might not have a ton of data, but a credible one will have a concrete plan for generating Real-World Evidence (RWE) and will be running prospective studies. You need to see proof that the AI’s insights from all that multimodal data actually lead to better clinical workflows, more accurate diagnoses, or improved patient outcomes.

Guardrail Design and Oversight Model

Multimodal AI can produce some very subtle and potentially risky interpretations. Because of that, strong guardrail design is critical. This means having mechanisms for a human-in-the-loop (a clinician, usually) to provide oversight, having a very clear definition of the AI’s intended use (is it just for Clinical Decision Support or is it a full-blown Diagnostic AI?), and being upfront about its limitations. Vendors who can show you a complete oversight model, explaining exactly how clinicians review the AI’s output and how they constantly monitor for model drift, are showing a real commitment to safety. Following GMLP (Good Machine Learning Practice) principles is another sign of a mature development process.

Regulatory Pathway and Compliance

A fuzzy or half-baked regulatory strategy is a dealbreaker. Good vendors know if their product is a SaMD and have already started or finished the right FDA submissions. For adaptive AI models that learn over time, a Predetermined Change Control Plan (PCCP) is a fantastic sign. It shows they’re working with regulators proactively to manage model updates without needing to resubmit from scratch every time. And past the FDA clearances, rock-solid cybersecurity, including HIPAA compliance and a SOC 2 Type II or HITRUST certification, is just the price of entry for protecting patient data.

“If a cardiac AI startup doesn’t have HITRUST or at least SOC 2 Type II, that’s an immediate red flag in diligence.”

Conclusion

Multimodal large language models are going to completely change clinical documentation audits by delivering incredible precision and efficiency. For VCs and growth equity investors, the opportunity is huge, but so are the liabilities. As an investor, you have to back the startups that are obsessed with auditability, transparent data sourcing, real clinical validation, smart guardrails, and a coherent regulatory plan. Doing so isn’t just about checking a compliance box, it’s the only way to lower your investment risk while helping build AI platforms that doctors can actually trust. The winners will be the ones who put clinical accountability first.